CJC-1295 / Mod-GRF 1-29: The Ipamorelin Stack Peptide for Sustained GH Release

See also: Fat Loss Peptides: The Complete Guide to AOD-9604, CJC-1295, and Tesamorelin — CJC-1295/Mod-GRF in the context of the full fat loss peptide stack, with body composition protocols and evidence comparison.

Turn Up the Volume on Your Own GH

Most people walk into the peptide world thinking growth hormone optimization means adding GH to a system that's running low. That's the rHGH model — exogenous human growth hormone, the stuff on every anti-aging clinic's price list. It works, but it overrides your physiology. Your pituitary, the gland that's been pulsing GH on its own schedule since you were born, basically gets benched.

The peptide path is different. The peptide path says: your pituitary still works. You just need to give it a louder signal.

CJC-1295 and its short-acting cousin Mod-GRF 1-29 are that signal. They're GHRH analogs — synthetic versions of the hypothalamic hormone that already tells your pituitary to release GH. Used solo, they make your natural GH pulses a little bigger. Stacked with Ipamorelin — a ghrelin mimetic that triggers an additional GH pulse through a completely separate pathway — they produce a synergistic, supra-physiological GH release that no single peptide can match.

Think of it this way. Ipamorelin is the trigger. It pulls the lever. It tells the pituitary, release now. CJC-1295 / Mod-GRF 1-29 is the volume dial. It controls how loud that release is. Pull the trigger without the dial turned up, and you get a modest pulse. Turn the dial up without pulling the trigger, and you get... not much, because GHRH alone is held back by somatostatin and the body's natural braking system. But pull the trigger while the dial is cranked, and the two effects multiply. The combined GH pulse is significantly larger than what either peptide produces alone — that's the textbook GHRH + GHRP synergy that's been described in human studies for over two decades.

This is why the Mod-GRF 1-29 + Ipamorelin stack has become the single most popular GH optimization protocol in the biohacker world. It's not because it's trendy. It's because the mechanism is elegant. You're not replacing GH — you're recruiting your own pituitary to do more of what it's already designed to do.

This article goes deep on the GHRH side of that equation. We'll untangle the naming mess (CJC-1295 with DAC vs without DAC vs Mod-GRF — three names, two different molecules, lots of confusion). We'll cover mechanism, the human research, dosing, side effects, and exactly how the stack works. By the end, you'll know whether this peptide belongs in your protocol — and which version to use.

What Is CJC-1295 / Mod-GRF 1-29?

This is where most people get tripped up, so let's clear it up first.

CJC-1295 is a brand name from a Canadian biotech company called ConjuChem, which originally developed it in the mid-2000s. The peptide they patented is a modified version of native GHRH(1-29) — the first 29 amino acids of human growth hormone-releasing hormone, which is the active fragment that does all the work. Native GHRH(1-29) has a half-life of about seven minutes in human plasma — it's degraded almost as fast as it's released. To make a viable drug, ConjuChem made two engineering changes:

1. Tetrasubstitution — they swapped out four amino acids in the GHRH(1-29) sequence (positions 2, 8, 15, and 27) to make the molecule resistant to enzymatic breakdown. This pushes the half-life from ~7 minutes to about 30 minutes.
2. DAC (Drug Affinity Complex) — they added a maleimidopropionic acid group that binds covalently to serum albumin. Once it's bound to albumin, the peptide essentially hides from kidney clearance and circulating proteases. Half-life shoots up from 30 minutes to roughly 8 days.

The DAC version is the original CJC-1295. The non-DAC version — just the tetrasubstituted GHRH(1-29) without the albumin-binding tail — is technically called CJC-1295 without DAC, but the more accurate name (and the one researchers prefer) is Mod-GRF 1-29 (Modified Growth Hormone-Releasing Factor, amino acids 1–29). They're the same molecule. "Mod-GRF 1-29" just avoids the confusion that comes from sharing a name with the long-acting version.

So: two molecules, three names.

• CJC-1295 with DAC: tetrasubstituted GHRH(1-29) + albumin-binding tail. Half-life ~8 days. Designed for twice-weekly dosing.
• Mod-GRF 1-29 (aka CJC-1295 without DAC): tetrasubstituted GHRH(1-29), no DAC. Half-life ~30 minutes. Designed for multiple daily injections to mimic natural pulsatile GH release.

Both bind the same receptor — the GHRH receptor on pituitary somatotroph cells, the GH-producing cells in your anterior pituitary. Both signal the same downstream cascade. The only meaningful difference is how long they stick around in your bloodstream.

This matters more than it sounds. Your body doesn't release GH in a steady drip — it releases it in discrete pulses, mostly during deep sleep. If you mimic that pulse pattern, you work with your physiology. If you flatten it out into a constant signal, you work against it. We'll come back to this in the comparison section, because it drives the whole biohacker preference between the two versions.

Mechanism of Action

Here's the chain of events. Your hypothalamus produces GHRH. GHRH travels through the hypophyseal portal blood system — a tiny vascular network that connects the hypothalamus directly to the anterior pituitary — and binds to GHRH receptors on somatotroph cells. The binding activates Gs proteins, which crank up cyclic AMP, which activates protein kinase A, which triggers stored GH granules to fuse with the cell membrane and release GH into circulation.

That's the natural pathway. CJC-1295 and Mod-GRF 1-29 ride exactly the same rails. They're GHRH receptor agonists. They bind the same site, activate the same second messengers, and trigger the same GH release. The only thing they change is the strength and duration of the signal.

But here's the part that makes the GHRH + GHRP stack so interesting: GHRH isn't the only signal that controls GH release. There's a second pathway — the ghrelin receptor (technically called GHSR-1a, growth hormone secretagogue receptor 1a), which also lives on somatotrophs. Ghrelin itself, and synthetic ghrelin mimetics like Ipamorelin, bind GHSR-1a and trigger GH release through a different signaling cascade (phospholipase C, IP3, calcium release).

When you activate both receptors simultaneously, the effect is more than additive. Multiple human studies have shown that GHRH + GHRP co-administration produces GH pulses two to five times larger than either peptide alone. This is the synergy biohackers care about.

The usual mental model is:

• GHRH (CJC-1295 / Mod-GRF 1-29) = amplitude. It increases the size of each GH pulse by recruiting more somatotrophs and getting them to release more GH per cell.
• GHRP (Ipamorelin, GHRP-2, GHRP-6) = frequency and trigger. It initiates GH pulses and reduces the influence of somatostatin — the inhibitory hormone that normally puts the brakes on GH release.

Ipamorelin specifically is the preferred GHRP for this stack because it's selective. GHRP-6 also stimulates cortisol, prolactin, and significant ghrelin-driven hunger. GHRP-2 stimulates cortisol and prolactin too, just less. Ipamorelin? Pure GH selectivity. No measurable cortisol bump, no prolactin spike, no hunger. That's why this exact combination — Mod-GRF 1-29 + Ipamorelin — has won the biohacker popularity contest. The amplitude dial is clean, the trigger is clean, the resulting pulse is clean.

One more mechanistic note worth understanding: somatostatin tone matters. Somatostatin is your body's GH brake. It rises and falls throughout the day, and when it's high, even a big GHRH signal gets blunted. GHRPs like Ipamorelin partially suppress somatostatin's effect, which is part of why combining the two peptides produces a larger pulse than the math would predict. The GHRP isn't just adding a separate signal — it's removing the brake so the GHRH signal can fully express itself.

CJC-1295 vs Mod-GRF 1-29 — Which Should You Use?

Both molecules activate the same receptor. The question is which dosing pattern fits your physiology.

The single biggest functional difference is GH bleed.

With CJC-1295 DAC's 8-day half-life, the peptide is essentially active in your bloodstream 24/7 for the entire cycle. That means the GH-releasing signal is also constant. Instead of a clean pulse — rise, peak, fall — you get a flattened, elevated GH baseline. Your somatotrophs are being mildly stimulated all the time. This is not how natural GH release works. Natural GH lives in spikes, particularly during sleep, with long periods of near-zero output in between. The receptor cells expect that pattern. The downstream tissues that respond to GH (the liver, which produces IGF-1; muscle; fat) also expect that pattern.

Flattened, continuous GH elevation might sound like a good thing — more is better, right? — but the research on rHGH abuse and acromegaly suggests otherwise. The pulsatile pattern of GH release seems to matter for the downstream effects on tissue repair, body composition, and metabolic signaling. There's also a real concern that constant elevated GH leads to faster receptor downregulation and tachyphylaxis — your body just stops responding as well over time.

Mod-GRF 1-29 sidesteps all of this. Inject 100 mcg subcutaneously, you get a clean GH pulse over the next 60–90 minutes, and then your GH levels return to baseline. Inject again 6 hours later, you get another clean pulse. The pattern looks much more like what your body does on its own — just with bigger amplitudes. This is the version most experienced biohackers run.

The honest recommendation: for most people stacking with Ipamorelin and trying to amplify natural GH pulses, Mod-GRF 1-29 is the better choice. Cleaner physiology, more responsive long-term, easier to time with a GHRP, and easier to cycle off cleanly. CJC-1295 DAC has its niche — people who absolutely won't comply with multiple daily injections, or who want a smoother but blunter IGF-1 elevation for a specific reason — but it's not the default.

From here on out, when this article says "the stack," we mean Mod-GRF 1-29 + Ipamorelin. That's the protocol.

Clinical & Research Evidence

Here's where we need to be honest about what we actually know.

The peer-reviewed clinical research on CJC-1295 is almost entirely on the DAC version, not Mod-GRF 1-29. That's because CJC-1295 with DAC was being developed as a pharmaceutical — ConjuChem ran formal Phase I/II trials in the mid-2000s. The most-cited paper is Teichman et al. (2006), published in The Journal of Clinical Endocrinology & Metabolism. They administered single subcutaneous doses of CJC-1295 DAC (ranging from 30 to 250 mcg/kg) to healthy adults and tracked GH and IGF-1 over the following days.

The results were striking:

• Mean GH levels increased 2- to 10-fold over baseline within hours of injection.
• IGF-1 levels rose 1.5- to 3-fold over baseline and stayed elevated for 7 to 10 days after a single dose.
• The effects were dose-dependent.
• The peptide was well tolerated. The main side effects reported were injection-site reactions and mild flushing.

Follow-up studies with weekly dosing showed sustained IGF-1 elevation over the dosing period. From a pure "does it work" standpoint, the Teichman data is convincing. CJC-1295 DAC reliably elevates GH and IGF-1 in healthy humans.

The research base for Mod-GRF 1-29 specifically is thinner. There's some pharmacokinetic work showing the expected 30-minute half-life and the expected GHRH-receptor pharmacology. There are studies on the closely related sequence — native GHRH(1-29), often called sermorelin — which has actually been on the market as an approved pediatric GH-deficiency therapy for decades. The mechanism is shared. The pulsatile dosing data on Sermorelin reasonably extends to Mod-GRF 1-29, since they bind the same receptor and produce the same downstream cascade, just with a slightly longer half-life on the modified version.

What about combination studies — GHRH + GHRP together? There's a meaningful body of work here, mostly using GHRH(1-29) plus GHRP-6 or GHRP-2, showing that combined administration produces dramatically larger GH pulses than either peptide alone. The synergy is well-documented. Studies specifically on Mod-GRF + Ipamorelin are mostly informal and community-driven (sleep tracking, body composition logs, IGF-1 panels from people running the stack), not formal RCTs.

The honest summary: the receptor pharmacology is rock solid. The single-peptide human data on CJC-1295 DAC is well-replicated. The GHRH + GHRP synergy is well-documented in principle. What's less well-documented is the specific long-term outcome data for the Mod-GRF + Ipamorelin stack at the doses biohackers run. The research base here is meaningfully smaller than what we have for Ipamorelin alone, and significantly smaller than for FDA-approved Sermorelin. This isn't a reason to avoid the stack — but it's a reason to keep expectations calibrated and to pay attention to your own labs (especially IGF-1) if you're running it.

The Ipamorelin + Mod-GRF 1-29 Stack

This is the protocol that drove this article. Let's walk through why it works, how to time it, and what to actually expect.

Why this stack: the two peptides target separate receptors with separate signaling cascades. Mod-GRF 1-29 hits the GHRH receptor (Gs / cAMP pathway). Ipamorelin hits the GHSR-1a ghrelin receptor (PLC / IP3 / calcium pathway). When you fire both at once, the somatotroph cells get two simultaneous "release GH now" signals through independent mechanisms. The result is a GH pulse 2–5x larger than either peptide produces alone, with no cortisol or prolactin spike (because Ipamorelin is selective) and no GH bleed (because Mod-GRF 1-29 clears in ~30 minutes).

It's the cleanest GH amplification protocol the peptide world has come up with. That's why it's the default for serious users running Ipamorelin.

Timing: inject both peptides simultaneously, mixed in the same syringe or back-to-back. Optimal windows:

• Pre-sleep (30–60 minutes before bed) — this is the highest-leverage timing because your largest natural GH pulse already happens during the first few hours of deep sleep. You're amplifying a wave that's about to break anyway. Many users report deeper, longer slow-wave sleep on this protocol, which is itself part of the recovery mechanism.
• Early morning, fasted — second-best window. Cortisol is naturally high in the morning and somatostatin tone is lower, so a GH pulse has room to grow. Just make sure you've fasted at least 2–3 hours before and won't eat for another 30–60 minutes after. Insulin and glucose both blunt the GH response.
• Optional mid-day, fasted — if you're running 2–3 daily injections, slot one between meals.

Expected outcomes (these are realistic, not hype):

• Better sleep quality, deeper slow-wave sleep — usually the first thing people notice, within the first 1–2 weeks.
• Improved recovery from training. Soreness clears faster, sessions feel less depleting.
• Body composition shifts over 8–12 weeks: modest lean mass increase, slow fat reduction (especially visceral fat). Don't expect dramatic numbers — this is GH optimization, not anabolic steroids.
• Skin and connective tissue improvements: better elasticity, faster healing of small cuts and joint nags. Collagen synthesis is downstream of GH and IGF-1.
• Subjective energy, sense of well-being. Mood often improves.
• IGF-1 elevation on labs — usually a 30–60% increase from baseline if dosing is appropriate.

What you should not expect: dramatic mass gains, rapid fat loss like a cutting cycle, or anything that looks like the results from synthetic GH at supraphysiological doses. This is amplification, not replacement. The ceiling is set by your own pituitary.

The stack pairs naturally with general peptide anti-aging protocols — particularly if longevity and recovery are higher on your priority list than raw performance gains.

Want the complete GH optimization protocol? The Peptide Stacking Guide covers every major stack including GHRH+GHRP combinations, timing windows, and dose-titration walkthroughs. Get the Stacking Guide →

Dosage & Protocols

Standard biohacker dosing, summarized cleanly:

Mod-GRF 1-29:

• 100 mcg per injection
• 1–3x daily (most users land on 2x — pre-sleep and morning)
• Subcutaneous (SubQ), usually into abdominal fat
• Always paired with Ipamorelin 100–300 mcg in the same shot
• Fasted state (2–3 hours since last meal, 30–60 minutes before next meal)

CJC-1295 with DAC (if you're using the long-acting version):

• 1–2 mg per injection
• Twice weekly (e.g., Monday + Thursday)
• SubQ
• Timing less critical due to long half-life, but pair Ipamorelin doses with the cleaner windows

Reconstitution: both peptides come as a lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water — typically 2 mL of bac water added to a 2 mg or 5 mg vial. The exact ratio determines how many units on your insulin syringe equal 100 mcg. Full walkthrough in our peptide reconstitution guide.

Storage: reconstituted peptide goes in the fridge. Use within 30 days. Lyophilized vials store at room temperature short-term, freezer for long-term. See the peptide storage temperature guide for the full breakdown.

Cycle structure: the standard recommendation is 12 weeks on, 4 weeks off. The off period matters. Continuous GHRH-receptor stimulation eventually leads to receptor downregulation and a blunted response — your pulses get smaller, your IGF-1 stops climbing, the protocol stops working. The 4-week washout lets the receptor population reset. Some users run shorter on/off (8 weeks on, 4 off) and report cleaner long-term sensitivity.

Why fasted timing matters: elevated insulin directly suppresses GH release. So does elevated blood glucose. Eat a big carb meal, inject Mod-GRF + Ipamorelin 30 minutes later, and you'll mute the pulse you just paid for. The fasted window is non-negotiable for getting full value from each injection.

Side Effects & Safety

The stack is generally well-tolerated. Most people who report problems are either dosing too high or stacking with too many other peptides at once.

Common, usually mild:

• Water retention — especially in the first 2–3 weeks. GH elevation increases sodium retention. Usually resolves on its own.
• Tingling or numbness in hands and feet — classic GH-related side effect (mild carpal tunnel symptoms in some users). Reduces with dose adjustment.
• Transient flushing or warmth immediately after injection — vasodilation from the GHRH signal. Lasts a few minutes. Harmless.
• Injection site reactions — small red bump or itch. Rotate sites, switch to a smaller-gauge needle, and it usually clears.
• Vivid dreams — especially if dosing pre-sleep. Some people love this, some find it disruptive.
• Lightheadedness if injecting too quickly or while standing — sit down for the first few injections until you know how you respond.

Specific to CJC-1295 with DAC:

• GH bleed and continuously elevated baseline can lead to more pronounced water retention, sometimes mild joint puffiness, and a higher likelihood of insulin sensitivity changes over long cycles.
• Some users report a "foggy" feeling on the DAC version that they don't get on Mod-GRF 1-29 — likely related to the lack of pulsatile pattern.

Less common but worth knowing:

• Reduced insulin sensitivity over long cycles. GH is counter-regulatory to insulin. Watch fasting glucose if you're cycling longer than 12 weeks.
• Headaches in some users, usually dose-related.

Hard contraindications — do not use:

• Active malignancy of any kind. GH and IGF-1 elevation may accelerate growth of existing cancers. This is a hard line.
• History of acromegaly or pituitary tumor.
• Pregnancy or breastfeeding.
• Active diabetic retinopathy.
• Severe untreated insulin resistance or uncontrolled diabetes.

Honest framing on long-term safety: the peer-reviewed safety database for chronic GHRH-analog use in healthy adults is limited. Most safety data we have is from Sermorelin (close cousin, FDA-approved) and from rHGH replacement therapy in adults with documented deficiency. Neither maps perfectly to a healthy biohacker running the Mod-GRF + Ipamorelin stack for years. The mechanism doesn't suggest serious long-term risks at the doses used — but we don't have decades of follow-up either.

More on adverse events and how to interpret them in our peptide side effects guide.

Who It's For / Who Should Skip It

This stack makes sense for you if:

• You've already run Ipamorelin solo for a cycle or two and want to amplify the results.
• Your goals are improved body composition, recovery, sleep quality, or collagen/joint health.
• You're a performance athlete looking for recovery edge without the regulatory or health risks of synthetic GH.
• You're comfortable with multiple daily SubQ injections and basic timing discipline (fasted windows).
• You're willing to do basic bloodwork (IGF-1, fasting glucose, HbA1c) once a quarter to monitor response.
• You're past 30 and feeling the natural GH decline that starts in the late 20s.

You should probably skip it if:

• You're new to peptides. Start with Ipamorelin alone or Sermorelin alone first. You need a baseline before you start stacking.
• You want a simple, one-injection-per-week protocol. CJC-1295 DAC might fit, but Mod-GRF + Ipamorelin is a higher-touch regimen.
• You have any active cancer history. Hard skip.
• You're under 25 and your endogenous GH is already maximal. The stack does very little when your baseline is already high.
• You're not willing to fast around injections. The protocol's value collapses if you're hitting it post-meal.
• You're trying to substitute peptides for fundamentals. Bad sleep, undereating protein, no resistance training — those will tank your GH response regardless of what you inject.

Conclusion: The Logical Next Step

If you read our Ipamorelin article and ran the protocol for a cycle, this is the natural next move. Ipamorelin alone amplifies your existing GH pulse frequency with a clean, selective signal — no cortisol, no prolactin, no hunger. It's a beautiful single-peptide protocol. But it leaves amplitude on the table.

Adding Mod-GRF 1-29 is how you take that amplitude back.

The two peptides target two different receptors. They trigger two different signaling cascades. They converge on the same outcome — a larger, cleaner GH pulse — through complementary mechanisms. The result is a protocol that's more physiological than synthetic GH, more potent than either peptide alone, and grounded in real receptor pharmacology that's been described in human studies for the better part of two decades.

The whole GHRH + GHRP framework is what serious biohackers run. Mod-GRF 1-29 + Ipamorelin is the cleanest expression of that framework available right now. It's the version that respects pulsatile physiology, doesn't blunt your downstream signaling, doesn't spike cortisol or prolactin, and gives you predictable IGF-1 elevation that you can verify on labs.

It's not magic. It won't replace training, sleep, or protein. It won't turn you into someone you're not. What it will do — when stacked correctly, dosed conservatively, and cycled with respect for the pituitary — is amplify the recovery and body composition signal your body is already trying to send.

If you're reading this article, you're probably ready for it.

Ready to go deeper? Browse the full Peptide 101 library → — every major peptide, every major stack, every protocol detailed and current.